Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Vaishali R. Moulton,Abel Suárez-Fueyo,Esra Meidan,Esra Meidan,Hao Li,Masayuki Mizui,George C. Tsokos +6 more
Reads0
Chats0
TLDR
Novel observations have provided an improved understanding of the contribution of tissue-specific factors and associated damage, T and B lymphocytes, as well as innate immune cell subsets and their corresponding abnormalities.About:
This article is published in Trends in Molecular Medicine.The article was published on 2017-07-01 and is currently open access. It has received 288 citations till now. The article focuses on the topics: Immune dysregulation & Autoimmunity.read more
Citations
More filters
Journal ArticleDOI
Sex Hormones in Acquired Immunity and Autoimmune Disease.
TL;DR: The role of sex hormones particularly estrogen, in the adaptive immune response, in health, and autoimmune disease with an emphasis on systemic lupus erythematosus is focused on.
Journal ArticleDOI
Autoimmunity and organ damage in systemic lupus erythematosus
TL;DR: Tsokos reviews how the genetic, epigenetic and microbial environments influence innate and adaptive immune cells to drive immunopathology and organ damage in systemic lupus erythematosus.
Journal ArticleDOI
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases
Kübra Bunte,Thomas Beikler +1 more
TL;DR: A review of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the pathogenesis of IMIDs aims to review the association of these IMIDs with periodontitis and briefly discusses the therapeutic potential of agents that modulate the IL
Journal ArticleDOI
Regulatory T cells in the treatment of disease
TL;DR: The current progress in modulating Treg cells in autoimmune disorders, transplantation and cancer is described to promote antitumour immunity and regression.
Journal ArticleDOI
Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.
TL;DR: A better understanding of the molecular defects including signaling events and gene regulation underlying the dysfunctional T cells in SLE is necessary to pave the path for better management, therapy, and perhaps prevention of this complex disease.
References
More filters
Journal ArticleDOI
Identification of a factor that links apoptotic cells to phagocytes
Rikinari Hanayama,Masato Tanaka,Keiko Miwa,Azusa Shinohara,Akihiro Iwamatsu,Shigekazu Nagata +5 more
TL;DR: Results indicate that milk fat globule-EGF-factor 8 secreted from activated macrophages binds to apoptotic cells, and brings them to phagocytes for engulfment.
Journal ArticleDOI
C1q and Mannose Binding Lectin Engagement of Cell Surface Calreticulin and Cd91 Initiates Macropinocytosis and Uptake of Apoptotic Cells
Carol Anne Ogden,Aimee deCathelineau,Peter R. Hoffmann,Donna L. Bratton,Berhane Ghebrehiwet,Valerie A. Fadok,Peter M. Henson +6 more
TL;DR: Evidence is provided that C1q and mannose binding lectin (MBL), a member of the collectin family of proteins, bind to apoptotic cells and stimulate ingestion of these by ligation on the phagocyte surface of the multifunctional protein, calreticulin.
Journal ArticleDOI
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill,C. Michael Neuwelt,Daniel J. Wallace,Joseph C. Shanahan,Kevin Latinis,Jim C. Oates,Tammy O. Utset,Caroline Gordon,David A. Isenberg,Hsin Ju Hsieh,David Zhang,Paul Brunetta +11 more
TL;DR: The EXPLORER trial enrolled patients with moderately-to-severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse, and no differences were noted between placebo and rituximab in the primary and secondary end points.
Journal ArticleDOI
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study†
Brad H. Rovin,Richard Furie,Kevin Latinis,R. John Looney,Fernando C. Fervenza,Jorge Sánchez-Guerrero,Romeo Maciuca,David Zhang,J Garg,Paul Brunetta,Gerald B. Appel +10 more
TL;DR: Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment.
Journal ArticleDOI
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases
TL;DR: Several pDC receptors negatively regulate type I IFN responses by pDCs during viral infection and for normal homeostasis, which normally prevents pDC responses to them.
Related Papers (5)
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more